Clinical Trials in Mexico

There are about 2991 clinical studies being (or have been) conducted in Mexico.
The country of the clinical trial is determined by the location of where the clinical research is being studied.
Most studies are often held in multiple locations & countries.

GSK3117391 has the potential to complement existing therapies in the treatment of chronic
inflammatory disorders such as rheumatoid arthritis (RA). This study will evaluate the
efficacy, safety and tolerability of oral GSK3117391 (Dose A) administered to subjects with
severe RA despite treatment with disease-modifying anti-rheumatic drugs (DMARDs). This is a
randomised, double-blind (sponsor open), multicentre, placebo-controlled, parallel group
study. The total maximum study duration is approximately 10 weeks. Following a screening
period of up to 28 days, subjects will be randomized (1:1) to placebo or GSK3117391 (Dose A)
administered orally for a period of 28 days. Subjects will be followed up for 7 to 14 days
post final dose. Approximately 40 subjects with severe RA will be randomised into the study.

This study will compare safety and efficacy of a generic rifaximin tablet to the reference
listed drug in the treatment of travelers' diarrhea. Additionally both the generic and
reference formulations will be tested for superiority against a placebo tablet.

The primary objective of this study is to evaluate the efficacy of treatment with either
lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's
syndrome as measured by the change from baseline in ESSDAI at Week 12 between active
treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.

The purpose of this study is to assess the efficacy of ustekinumab, in adult anti-TNF(alpha)
refractory participants with active radiographic axial spondyloarthritis (AxSpA), as measured
by the reduction in signs and symptoms of radiographic AxSpA.

The purpose of this study is to assess the efficacy and safety of ustekinumab in adult
participants with active nonradiographic axial spondyloarthritis (nr-AxSpA) measured by the
reduction in signs and symptoms of nonradiographic axial spondyloarthritis (nr-AxSpA).

The purpose of this study is to evaluate whether the combination of BMS-955176 with
atazanavir (ATV) [with or without ritonavir (RTV)] and dolutegravir (DTG) is efficacious,
safe, and well-tolerated in HIV-1 infected treatment experienced adults.

The primary objective of this study is to demonstrate the superiority of retosiban to prolong
pregnancy in females with spontaneous preterm labor compared with atosiban. This objective is
based on the hypothesis that prolonging the time to delivery in the absence of harm may
benefit the newborn, particularly in women who experience spontaneous preterm labor at early
gestational ages (GA). This study is designed to test this hypothesis through a direct
comparison with atosiban, a mixed oxytocin vasopressin antagonist indicated for short-term
use to delay imminent preterm birth in women between 24^0/7 and 33^6/7 weeks' gestation in
preterm labor. This is a randomized, double-blind, double-dummy study, which consists of 6
phases: Screening, Inpatient Randomized Treatment, Post Infusion Assessment, Delivery,
Maternal Post Delivery Assessment, and Neonatal Medical Review. Approximately 330 females
will be randomly assigned to retosiban or atosiban treatment in a 1:1 ratio. The duration of
any one subject's (maternal or neonatal) participation in the study will be variable and
dependent on GA at study entry and the date of delivery.

Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic
lupus erythematosus in male and female adults. Patients who qualify will be randomized to
either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the
initial 24 weeks of treatment and who are responding to therapy will have the option to
continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and
safety will be assessed over the course of the study through laboratory values, various
rating scales accepted in systemic lupus erythematosus studies and patient self reporting.

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The data & information found on this website is provided “AS IS” from ClinicalTrials.gov.
Neither we, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.